Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05417971 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 8 months later Jul 31, 2026 → Mar 31, 2027
See other at-risk trials from Northside Hospital, Inc.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 31, 2026 to Mar 31, 2027
    • Study completion pushed from Dec 31, 2026 to Dec 31, 2027
    • Eligibility criteria shortened, about 3 words
  2. Re-verified, no change to tracked fieldsv8
  3. Primary completion date: Jul 31, 2025 to Jul 31, 2026
    • Study completion date: Dec 31, 2025 to Dec 31, 2026
    v7
  4. Re-verified, no change to tracked fieldsv6
  5. Primary completion date: Jul 31, 2024 to Jul 31, 2025
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    v5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Primary completion date: Jul 2024 to Jul 31, 2024
    • Study completion date: Dec 2024 to Dec 31, 2024
    v3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 2022 to Aug 29, 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial will evaluate the safety and efficacy of RIC HIDT transplant protocol following fludarabine and intermediate-dose TBI 800 cGy utilizing PBSC as the stem cell source.
Trial Details
NCT Number NCT05417971
Lead Sponsor Northside Hospital, Inc.
Conditions
(from sponsor)		 Hematologic Malignancy
Related terms Hematologic Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov